scholarly journals HIV Viral Load Monitoring Frequency and Risk of Treatment Failure among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy

Author(s):  
Benjamin Young ◽  
Rachel L. D. Hart ◽  
Kate Buchacz ◽  
Mia Scott ◽  
Frank Palella ◽  
...  
PLoS ONE ◽  
2010 ◽  
Vol 5 (11) ◽  
pp. e15051 ◽  
Author(s):  
Vanja Romih ◽  
Snježana Židovec Lepej ◽  
Kornelija Gedike ◽  
Davorka Lukas ◽  
Josip Begovac

2019 ◽  
Vol 71 (4) ◽  
pp. 1017-1021
Author(s):  
Victor Ssempijja ◽  
Martha Nason ◽  
Gertrude Nakigozi ◽  
Anthony Ndyanabo ◽  
Ron Gray ◽  
...  

Abstract Background After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure. Methods The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months. Results Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%. Conclusions Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.


2021 ◽  
Vol 70 (21) ◽  
pp. 775-778
Author(s):  
Shirley Lee Lecher ◽  
Peter Fonjungo ◽  
Dennis Ellenberger ◽  
Christiane Adje Toure ◽  
George Alemnji ◽  
...  

2002 ◽  
Vol 29 (3) ◽  
pp. 270-274
Author(s):  
Christine Laine ◽  
Daozhi Zhang ◽  
Walter W. Hauck ◽  
Barbara J. Turner

BMJ ◽  
2011 ◽  
Vol 343 (nov09 2) ◽  
pp. d6884-d6884 ◽  
Author(s):  
J. G. Kahn ◽  
E. Marseille ◽  
D. Moore ◽  
R. Bunnell ◽  
W. Were ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Bradley T. Williamson ◽  
Heather A. Leitch

Introduction. In advanced HIV prior to combination antiretroviral therapy (ART), dysplastic marrow changes occurred and resolved with ART. Few reports of myelodysplastic syndromes (MDS) in well-controlled HIV exist and management is undefined.Methods. Patients with well-controlled HIV and higher risk MDS were identified; characteristics, treatment, and outcomes were reviewed.Results. Of 292 MDS patients since 1996, 1 (0.3%) was HIV-positive. A 56-year-old woman presented with cytopenias. CD4 was 1310 cells/mL and HIV viral load <40 copies/mL. Bone marrow biopsy showed RCMD and karyotype included del(5q) and del(7q); IPSS was intermediate-2 risk. She received azacitidine at 75% dose. Cycle 2, at full dose, was complicated by marrow aplasia and possible AML; she elected palliation. Three additional HIV patients with higher risk MDS, aged 56–64, were identified from the literature. All had deletions involving chromosomes 5 and 7. MDS treatment of 2 was not reported and one received palliation; all died of AML.Conclusion. Four higher risk MDS in well-controlled HIV were below the median age of diagnosis for HIV-negative patients; all had adverse karyotype. This is the first report of an HIV patient receiving MDS treatment with azacitidine. Cytopenias were profound and dosing in HIV patients should be considered with caution.


2017 ◽  
Vol 20 ◽  
pp. e25003 ◽  
Author(s):  
Sheree R Schwartz ◽  
Matthew M Kavanagh ◽  
Jeremy Sugarman ◽  
Sunil S Solomon ◽  
Illiassou M Njindam ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document